We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ROIV market cap is 7.94B. The company's latest EPS is USD -0.2530 and P/E is -45.53.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 28.93M | 55.13M | -42.67M | 9.02M | 7.57M |
| Operating Income | -266M | -230.57M | -323.76M | -274.38M | -281.86M |
| Net Income | -151.12M | 95.3M | -230.18M | 169.38M | -206.48M |
| Year End March 30 2025 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 23.8M | 55.29M | 61.28M | 124.8M | 29.05M |
| Operating Income | -1.07B | -1.35B | -1.18B | -1.11B | -1.11B |
| Net Income | -809.23M | -845.26M | -1.01B | 4.35B | -171.98M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 7.22B | 6.5B | 6.21B | 5.79B | 5.44B |
| Total Liabilities | 773.95M | 601.16M | 625.99M | 256.38M | 249.74M |
| Total Equity | 6.45B | 5.9B | 5.58B | 5.54B | 5.19B |
| Year End March 30 2025 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.59B | 2.59B | 2.39B | 7.22B | 5.44B |
| Total Liabilities | 527.69M | 523.7M | 782.02M | 773.95M | 249.74M |
| Total Equity | 2.04B | 2.04B | 1.61B | 6.45B | 5.19B |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -765.27M | -192.83M | -459.64M | -666.89M | -839.45M |
| Investing | 5.2B | -965k | -3.29B | -2.84B | -1.77B |
| Financing | 419.36M | -660.62M | -769.69M | -1.04B | -1.22B |
| Year End March 30 2025 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -552.14M | -677.73M | -843.39M | -765.27M | -839.45M |
| Investing | -31.7M | 303.3M | -44.27M | 5.2B | -1.77B |
| Financing | 456.26M | 306.79M | 499.46M | 419.36M | -1.22B |
| Market Cap | 7.94B |
| Price to Earnings Ratio | -45.53 |
| Price to Sales Ratio | 269.79 |
| Price to Cash Ratio | 2.88 |
| Price to Book Ratio | 1.51 |
| Dividend Yield | - |
| Shares Outstanding | 679.81M |
| Average Volume (1 week) | 9.42M |
| Average Volume (1 Month) | 6.48M |
| 52 Week Change | 9.05% |
| 52 Week High | 13.055 |
| 52 Week Low | 8.73 |
| Spread (Intraday) | 0.17 (1.46%) |
| Company Name | Roivant Sciences Ltd |
| Address |
clarendon house hamilton D0 HM11 |
| Website | https://www.roivant.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
